×
About 5,397 results

ALLMedicine™ Polycythemia Vera Center

Research & Reviews  2,549 results

Management of hydroxyurea resistant or intolerant polycythemia vera.
https://doi.org/10.1080/10428194.2021.1901092
Leukemia & Lymphoma; Raman I, Pasricha SR et. al.

May 5th, 2021 - Polycythemia vera is a Philadelphia negative myeloproliferative neoplasm characterized by erythrocytosis in which the major cause of morbidity and mortality is thrombosis. Aspirin and hematocrit reduction by venesection or cytoreductive therapy ar...

Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
https://doi.org/10.1016/j.clml.2021.03.005
Clinical Lymphoma, Myeloma & Leukemia; Alshemmari SH, Rajan R et. al.

Apr 16th, 2021 - Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell disorders that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). This study examines the driver mutatio...

Reflections on the unexpected laboratory finding of hemorheological alterations observe...
https://doi.org/10.1016/j.mvr.2021.104171
Microvascular Research; Caimi G, Lo Presti R et. al.

Apr 16th, 2021 - Hyperviscosity syndrome is a clinical condition characterized by the slowing of blood flow through the vessels and it may be associated with several diseases. The nosographic classification of primary hyperviscosity conditions (Wells classificatio...

Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A...
https://doi.org/10.1002/ajh.26186
American Journal of Hematology; Gangat N, Guglielmelli P et. al.

Apr 12th, 2021 - Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed/refractory setting. The current multicenter study retrospectively examined Ven ...

see more →

Guidelines  11 results

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx

Aug 16th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or ...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018.
https://doi.org/10.6004/jnccn.2017.0157
Journal of the National Comprehensive Cancer Network : JN... Mesa RA, Jamieson C et. al.

Oct 6th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018
http://www.jnccn.org/content/15/10/1193.full
Mesa, R.,et al

Sep 30th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh.

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Onco...
https://doi.org/10.6004/jnccn.2016.0169
Journal of the National Comprehensive Cancer Network : JN... Mesa R, Jamieson C et. al.

Dec 13th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs). The diagn...

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
http://www.jnccn.org/content/14/12/1572.full
Mesa, R.,et al

Nov 30th, 2016 - Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs). The diagn.

see more →

Drugs  4 results see all →

Clinicaltrials.gov  2,665 results

Management of hydroxyurea resistant or intolerant polycythemia vera.
https://doi.org/10.1080/10428194.2021.1901092
Leukemia & Lymphoma; Raman I, Pasricha SR et. al.

May 5th, 2021 - Polycythemia vera is a Philadelphia negative myeloproliferative neoplasm characterized by erythrocytosis in which the major cause of morbidity and mortality is thrombosis. Aspirin and hematocrit reduction by venesection or cytoreductive therapy ar...

Analysis of Common Driver Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
https://doi.org/10.1016/j.clml.2021.03.005
Clinical Lymphoma, Myeloma & Leukemia; Alshemmari SH, Rajan R et. al.

Apr 16th, 2021 - Philadelphia-negative myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell disorders that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). This study examines the driver mutatio...

Reflections on the unexpected laboratory finding of hemorheological alterations observe...
https://doi.org/10.1016/j.mvr.2021.104171
Microvascular Research; Caimi G, Lo Presti R et. al.

Apr 16th, 2021 - Hyperviscosity syndrome is a clinical condition characterized by the slowing of blood flow through the vessels and it may be associated with several diseases. The nosographic classification of primary hyperviscosity conditions (Wells classificatio...

Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A...
https://doi.org/10.1002/ajh.26186
American Journal of Hematology; Gangat N, Guglielmelli P et. al.

Apr 12th, 2021 - Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed/refractory setting. The current multicenter study retrospectively examined Ven ...

see more →

News  161 results

Fast Five Quiz: Test Your Knowledge on Key Aspects of Heart Failure
https://reference.medscape.com/viewarticle/893861_2

Feb 6th, 2020 - Because of increased myocardial oxygen consumption and demand beyond a critical level, the following high-output states can precipitate the clinical presentation of heart failure: Profound anemia Thyrotoxicosis Myxedema Paget disease of bone Albri...

Weight Gain, Hypertension Seen With Ruxolitinib
https://www.staging.medscape.com/viewarticle/921469

Nov 17th, 2019 - Real-world data from a retrospective study suggest that patients who are taking ruxolitinib (Jakafi, Incyte), which is approved for the treatment of myeloproliferative neoplasms such as polycythemia vera and myelofibrosis, experience weight gain t...

Weight Gain, Hypertension Seen With Ruxolitinib
https://www.medscape.com/viewarticle/921469

Nov 17th, 2019 - Real-world data from a retrospective study suggest that patients who are taking ruxolitinib (Jakafi, Incyte), which is approved for the treatment of myeloproliferative neoplasms such as polycythemia vera and myelofibrosis, experience weight gain t...

Hematocrit (HCT) Levels and Thrombotic Events Among US Veterans With Polycythemia Vera
https://www.mdedge.com/fedprac/avaho/article/207808/hematology/hematocrit-hct-levels-and-thrombotic-events-among-us?channel=53
Kambhampati S, Parasuraman S et. al.

Sep 9th, 2019 - Background: Thrombotic events (TEs) are a leading cause of death in patients with polycythemia vera (PV), contributing to lower overall survival compared with age/sex-matched controls. This analysis evaluated the relationship between HCT levels an.

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
https://ir.celgene.com/press-releases/press-release-details/2019/US-FDA-Approves-INREBIC-Fedratinib-as-First-New-Treatment-in-Nearly-a-Decade-for-Patients-With-Myelofibrosis/default.aspx

Aug 16th, 2019 - Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or ...

see more →

Patient Education  7 results see all →